instructor

Name 4

Presentand Future of Breast Cancer Management

Thearticle “Personalized medicine: present and future of breast cancermanagement” addresses the recent advancements in the fields ofdiagnosis and treatment of breast cancer. The article was written byRenaud Sabatier, Anthony Gonçalves, and François Bertucci andpublished by Elsevier in 2014. The authors identified differentmolecular subtypes associated with breast cancer. The use of moderntechniques (such as in situ hybridization) has allowed theresearchers to identify various molecular subtypes of breast cancer,which include Lumina A, basal-like, luminal B, Her2-enriched, andnormal-like. The discovery that breast cancer is a heterogeneousillness has necessitated the use of personalized medicine to managebreast cancer. This means that patients with different subtypes ofbreast cancer should be treated using different therapeuticapproaches. The authors conclude that personalized medicine is beingapplied in metastatic as well as adjuvant settings to managementbreast cancer more effectively.

Thefindings reported in the article have three major benefits to breastcancer patients as well as the health care professionals. First, theauthors put it cleat that breast cancer is a heterogeneous disease(Sabatier 4). This means that the molecular components causing thedisease can vary from one person to another. This disproves thegeneral perception among the health care professional that breastcancer is a homogeneous disease that can be managed using similarapproaches in all patients. Secondly, the research indicates that thedelivery of personalized medication for breast cancer increases theoutcome of effective therapeutic approaches. This means that patientswho receive personalized therapy have better recovery than patientswho receive generalized treatment. This is important information thatwill change the conventional treatment approach to breast cancer,thus enhancing the patient outcome. Third, the research puts moreemphasis on the usefulness of the modern technology in investigatingthe causes and possible treatment for breast cancer. The throughputtechnology allows researchers to investigate the disease at themolecular, which in turn results in the discovery of the mosteffective therapeutic approaches.

Theresearch has social and economic implications for the society. Theuse of personalized medication improves treatment outcome, which islikely to reduce the number of deaths caused by the breast cancer.This will in turn enhance the well being of the society. It is alsoevident that breast cancer affects individuals of one gender, women,which implies that the discovery of more effective medication willsave this population the life-threatening disease. In addition,effective recovery means that there will be a decrease in the cost oftreatment since the duration of hospitalization and the amount ofdrugs required to treat breast cancer will be reduced. This is aneconomic benefit to the patient and the society at large.

Inconclusion, the article “Personalized medicine: present and futureof breast cancer management” addresses the issue of personalizedtherapy for breast cancer. The article has successfully put it clearthat breast cancer is a heterogeneous disease. This means that breastcancer occurs in different subtypes, each requiring a different typeof medication. Personalized medication improves the treatmentoutcome, which in turn reduces the cost of treatment and deathscaused by breast cancer. In essence, the research indicates thatpersonalized therapy has both social (including the improvement inthe wellbeing of the society) and economic (including the reducedcost of breast cancer treatment) implications.

Workscited

Sabatier,R., Gonçalves, A. and Bertucci, F. “Personalized medicine: Presentand future of breast cancer management”. CriticalReview in Oncology91.3 (2014): 223-233. DOI:10.1016/j.critrevonc.2014.03.002